[1] Criteria for diagnosis of Behçet's disease. International study group for Behçet's disease[J]. Lancet, 1990, 335:1078-1080.
[2] Noel N, Bernard R, Wechsler B, Resche-Rigon M, Depaz R, Le Thi Huong Boutin D, Piette JC, Drier A, Dormont D, Cacoub P, Saadoun D. Long-term outcome of neuro-Behcet's disease[J]. Arthritis Rheumatol, 2014, 66:1306-1314.
[3] Kalra S, Silman A, Akman Demir G, Bohlega S, Borhani-Haghighi A, Constantinescu CS, Houman H, Mahr A, Salvarani C, Sfikakis PP, Siva A, Al-Araji A. Diagnosis and management of Neuro-Behcet's disease:international consensus recommendations[J]. J Neurol, 2014, 261:1662-1676.
[4] International Team for the Revision of the International Criteria for Behcet's Disease (ITR-ICBD). The international criteria for Behcet's disease (ICBD):a collaborative study of 27 countries on the sensitivity and specificity of the new criteria[J]. J Eur Acad Dermatol Venereol, 2014, 28:338-347.
[5] Piven VD, Krasnov VS, Lashok PA, Neofidoff NA, Bubnova EV, Totolyan NA. Behcet's disease with neurologic manifestations[J]. Zh Nevrol Psikhiatr Im S S Korsakova, 2019, 119:67-73.
[6] Borhani-Haghighi A, Kardeh B, Banerjee S, Yadollahikhales G, Safari A, Sahraian MA, Shapiro L. Neuro-Behcet's disease:an update on diagnosis, differential diagnoses, and treatment[J]. Mult Scler Relat Disord, 2019.[Epub ahead of print]
[7] Davatchi F, Chams-Davatchi C, Shams H, Shahram F, Nadji A, Akhlaghi M, Faezi T, Ghodsi Z, Sadeghi Abdollahi B, Ashofteh F, Mohtasham N, Kavosi H, Masoumi M. Behcet's disease:epidemiology, clinical manifestations, and diagnosis[J]. Expert Rev Clin Immunol, 2017, 13:57-65.
[8] Al-Araji A, Kidd DP. Neuro-Behçet's disease:epidemiology, clinical characteristics, and management[J]. Lancet Neurol, 2009, 8:192-204.
[9] Siva A, Kantarci OH, Saip S, Altintas A, Hamuryudan V, Islak C, Kocer N, Yazici H. Behcet's disease:diagnostic and prognostic aspects of neurological involvement[J]. J Neurol, 2001, 248:95-103.
[10] Kocer N, Islak C, Siva A, Saip S, Akman C, Kantarci O, Hamuryudan V. CNS involvement in neuro-Behcet syndrome:an MR study[J]. AJNR Am J Neuroradiol, 1999, 20:1015-1024.
[11] Farahangiz S, Sarhadi S, Safari A, Borhani-Haghighi A. Magnetic resonance imaging findings and outcome of neuro-Behcet's disease:the predictive factors[J]. Int J Rheum Dis, 2012, 15:E142-149.
[12] Bolek EC, Sari A, Kilic L, Kalyoncu U, Kurne A, Oguz KK, Topcuoglu MA, Ertenli I, Karadag O. Clinical features and disease course of neurological involvement in Behcet's disease:HUVAC experience[J]. Mult Scler Relat Disord, 2020, 38:101512.
[13] De Sousa DA, Mestre T, Ferro J. Response to comment on "Cerebral venous thrombosis in Behcet's disease:a systematic review" by Afshin Borhani-Haghighi and Anahid Safari[J]. J Neurol, 2011, 258:908-909.
[14] Uyguno?lu U, Siva A. Behçet's syndrome and nervous system involvement[J]. Curr Neurol Neurosci Rep, 2018, 18:35.
[15] Xu JL, Zhao JH, Fu J, Niu YX, Wei YH, Chen XH. Clinical analysis of 36 cases of neuro-Behcet's disease[J]. Zhong Feng Yu Shen Jing Ji Bing Za Zhi, 2010, 27:1007-1009.[徐佳亮, 赵久晗, 付峻, 牛英翔, 魏艳花, 陈晓虹. 神经白塞病36例临床分析[J]. 中风与神经疾病杂志, 2010, 27:1007-1009.]
[16] Houman MH, Neffati H, Braham A, Harzallah O, Khanfir M, Miled M, Hamzaoui K. Behcet's disease in Tunisia:demographic, clinical and genetic aspects in 260 patients[J]. Clin Exp Rheumatol, 2007, 25(4 Suppl 45):58-64.
[17] Ideguchi H, Suda A, Takeno M, Kirino Y, Ihata A, Ueda A, Ohno S, Baba Y, Kuroiwa Y, Ishigatsubo Y. Neurological manifestations of Behcet's disease in Japan:a study of 54 patients[J]. J Neurol, 2010, 257:1012-1020.
[18] Yan D, Liu J, Zhang Y, Yuan W, Xu Y, Shi J, Li C, Wang Y, Peng L, Yang Y, Zhou J, Wu D, Liu Z, Zeng X, Zhang F, Zheng W, Zhao Y. The clinical features and risk factors of parenchymal Neuro-Behcet's disease[J]. J Immunol Res, 2019:ID7371458.
[19] Kürtüncü M, Tüzün E, Akman-Demir G. Behçet's disease and nervous system involvement[J]. Curr Treat Options Neurol, 2016, 18:19.
[20] Hatemi G, Christensen R, Bang D, Bodaghi B, Celik AF, Fortune F, Gaudric J, Gul A, Kötter I, Leccese P, Mahr A, Moots R, Ozguler Y, Richter J, Saadoun D, Salvarani C, Scuderi F, Sfikakis PP, Siva A, Stanford M, Tugal-Tutkun I, West R, Yurdakul S, Olivieri I, Yazici H. 2018 update of the EULAR recommendations for the management of Behcet's syndrome[J]. Ann Rheum Dis, 2018, 77:808-818.
[21] Liu JJ, Hou YX, Zhang Li, Wu Di, Peng LY, Wu CY, Yang YJ, Zhang SZ, Zhou JX, Zheng WJ, Zeng XF. Infliximab for the treatment of severe and/or refractory neuro-Behcet disease[J]. Zhonghua Lin Chuang Mian Yi He Bian Tai Fan Ying Za Zhi, 2020, 14:118-123.[刘金晶, 侯云霞, 张莉, 吴迪, 彭琳一, 吴婵媛, 杨云娇, 张上珠, 周佳鑫, 郑文洁, 曾小峰. 英夫利西单抗治疗重症和(或)难治性神经白塞病的疗效及安全性[J]. 中华临床免疫和变态反应杂志, 2020, 14:118-123.]
[22] Greco A, De Virgilio A, Ralli M, Ciofalo M, Mancini P, Attanasio G, Vincentiis M, Lambiase A. Behçet's disease:new insights into pathophysiology, clinical features and treatment options[J]. Autoimmun Rev, 2018, 17:567-575.
[23] Caruso P, Moretti R. Focus on neuro-Behçet's disease:a review[J]. Neurol India, 2018, 66:1619-1628. |